(Reuters) - Medivation Inc's experimental prostate cancer pill caused fewer serious side effects in clinical trial patients than a placebo treatment, according to full results from a pivotal study announced on Tuesday. Medivation and partner Astellas Pharma Inc reported in November that the trial had been stopped early after it became clear that the drug, MDV3100, improved median overall ...